Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)

简要总结

主要结局

次要结局

• Relationship between prior number of PIs utilized and number of available (sensitive) PIs as determined by resistance testing(up to 45 days)
• Rationale reported for modifying or not modifying baseline ARV regimen after receiving resistance testing results(up to 45 days)
• Utilization (yes/no) of expert interpretation by a clinician after receiving resistance testing results(up to 45 days)
• The physician's assessment of whether the phenotypic testing (as part of combined testing) provided more information than the genotypic test alone did(up to 45 days)
• Protease inhibitor(s) (PI) identified by the clinician prior to resistance testing to which a patient's HIV-1 virus was thought to be susceptible(Day 1)
• PI that was discontinued or initiated after receiving resistance testing results(up to 45 days)
• Non-PI ARVs that were discontinued or initiated after receiving resistance testing results(up to 45 days)
• Physician reported limitations that influence access to resistance testing(day 1)
• Clinician reported reasons why tipranavir was or was not considered as an option for each patient(up to 45 days)